Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery

Expert Opinion on Drug Safety

Volumn 9, Issue 5, 2010, Pages 793-800

  Voûte, Michiel T ^a   Winkel, Tamara A ^a   Poldermans, Don ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular risk; Fluvastatin; Myocardial infarction; Perioperative therapy; Statins; Vascular surgery

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYCLOSPORIN; ERYTHROMYCIN; FLUINDOSTATIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MEVINOLIN; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRAVASTATIN; PROPOFOL; RIFAMPICIN; SIMVASTATIN; WARFARIN;

ABDOMINAL DISCOMFORT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAPEFRUIT JUICE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MUSCLE DISEASE; MYALGIA; MYOPATHY; MYOSITIS; NONHUMAN; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; VASCULAR SURGERY;

ADMINISTRATION, ORAL; ANESTHETICS; BIOTRANSFORMATION; CARDIAC SURGICAL PROCEDURES; CYTOCHROME P-450 ENZYME SYSTEM; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; MUSCULAR DISEASES; MYOCARDIAL ISCHEMIA; PLAQUE, ATHEROSCLEROTIC; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RUPTURE, SPONTANEOUS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77955971503     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.499120     Document Type: Review

References (40)

1. Gordon DJ, Rifkind BM. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents. Ann Intern Med 1987;107(5):759-761
2. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106(8):1024-1028
3. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J 2009;30(22):2769-2812
4. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999;10(6):543-559
5. Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct anti-inflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005;25(6):1231-1236
6. Van Kuijk JP, Flu WJ, Witteveen OP, et al. The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms. J Cardiovasc Surg (Torino) 2009;50(5):599-609
7. Yuan JN, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 1991;87(2-3):147-157
8. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992;32(7):630-8
9. Corsini A. Fluvastatin: effects beyond cholesterol lowering. J Cardiovasc Pharmacol Ther 2000;5(3):161-175
10. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001;40(4):263-281
11. Lawrence JM, Reckless JP. Fluvastatin. Expert Opin Pharmacother 2002;3(11):1631-1641
12. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/Lescol. pdf
13. Sabia H, Prasad P, Smith HT, et al. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 2001;37(5):502-511
14. Boersma E, Kertai MD, Schouten O, et al. Perioperative cardiovascular mortality in noncardiac surgery: validation of the Lee cardiac risk index. Am J Med 2005;118(10):1134-1141
15. Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009;361(10):980-989
16. Poldermans D. Statins and noncardiac surgery: current evidence and practical considerations. Cleve Clin J Med 2009;76(Suppl 4):S79-83
17. Benghozi R, Bortolini M, Jia Y, et al. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002;89(2):231-233
18. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-414
19. van der Graaf A, Nierman MC, Firth JC, et al. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. Acta Paediatr 2006;95(11):1461-1466
20. Hrab RV, Hartman HA, Cox RH Jr. Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology 1994;50(1):19-26
21. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 5th edition. Baltimore, Maryland; 1998. p. 630-632
22. Lye M, Valacio R, Reckless JP, et al. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin. Coron Artery Dis 1998;9(9):583-590
23. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001;111(5):390-400
24. Kline SS, Harrell CC. Potential warfarin-fluvastatin interaction. Ann Pharmacother 1997;31(6):790
25. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004;24(2):285-290
26. Kokudai M, Inui N, Takeuchi K, et al. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. J Clin Pharmacol 2009;49(5):568-573
27. Yang LQ, Yu WF, Cao YF, et al. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003;9(9):1959-1962
28. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos 1996;24(9):932-939
29. McDonnell CG, Malkan D, Van Pelt FD, Shorten GD. Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. Eur J Anaesthesiol 2003;20(8):662-667
30. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105(12):1446-1452
31. Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007;100(2):316-320
32. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003;107(14):1848-1851
33. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery withatorvastatin: a randomized trial. J Vasc Surg 2004;39(5):967-75; discussion 975-1966
34. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 2004;28(4):343-352
35. ONeil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005;45(3):336-342
36. Lindenauer PK, Pekow P, Wang K, et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004;291(17):2092-2099
37. Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009;249(6):921-926
38. Yood MU, McCarthy BD, Kempf J, et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J 2006;152(4):777-784
39. Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008;117(12):1537-1544
40. Ito T, Ikeda U, Shimpo M, et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther 2002;16(2):121-126